HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications

Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 420

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

IPMCMED03_041

تاریخ نمایه سازی: 6 خرداد 1398

Abstract:

Epigenetics is independent of the sequence events that physically affect the condensing of chromatin and genesexpression. The unique epigenetic memories of various cells trigger exclusive gene expression profiling.According to different studies, the aberrant epigenetic signatures and impaired gene expression profiles aremaster occurrences in cancer cells in which oncogene and tumor suppressor genes are affected. Owing to thefacts that epigenetic modifications are performed earlier than expression and are reversible, the epigenetic reprogramming of cancer cells could be applied potentially for their prevention, control, and therapy. The disruption of the acetylation signature, as a master epigenetic change in cancers, is related to the expression and the activity of HDACs. In this context, class I HDACs play a significant role in the regulation of cell proliferation and cancer. More recently, cancer stem cell (CSC) has been introduced as a minority population of tumor that is responsible for invasiveness, drug resistance, and relapse of cancers. It is now believed that controlling CSC via epigenetic reprogramming such as targeting HDACs could be helpful in regulating the acetylation pattern of chromatin. Recently, a number of reports have introduced some phytochemicals as HDAC inhibitors. The use of phytochemicals with the HDAC inhibition property could be potentially efficient in overcoming the mentioned problems of CSCs. This review presents a perspective concerning HDAC-targeted phytochemicals to control CSC in tumors. Hopefully, this new route would have more advantages in therapeutic applications and prevention against cancer.

Keywords:

Cancer , HDAC , HDACi , CSCs , Phytochemical , HDAC class I , Herbal medicine No conflicts of interest

Authors

Sahar Bayat

Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Mohammad Reza Alivand

Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Sima Mansoori Derakhshan

Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran